The Hydration Pharmaceuticals Company Limited

Q3 FY23 Quarterly Report and Appendix 4c: Material YoY Reduction in Cash Burn and Ongoing Revenue Growth

Hydration solutions company The Hydration Pharmaceuticals Company Limited (ASX: HPC) (“Hydralyte North America” or “the Company”) is pleased to provide the following update on its operational and financial performance for the three-month period ended 30 September 2023 (the “quarter”).


KEY HIGHLIGHTS

  • Net sales of US$2.60m achieved in Q3 FY23 – 7% increase on PCP (Q3 FY2022: US$2.43m) and tenth straight quarter of sales growth on a trailing 12-month basis
  • Q3 FY23 is the second highest ever quarterly sales result and consolidates summer month momentum from strong Q2 FY23 net sales
  • Gross margin increased 8ppt to 58% on prior quarter (Q2 FY23: 50%) – YoY Gross profit dollars up 23% to a record US$1.51m from Q3 FY22 (US$1.23m)
  • Net cash used in operating activities down 47% on PCP to US$1.46m (Q3 FY22: US$2.78m) and in line with previous quarter – initiatives in place expected to reduce this further
  • Marketing costs as a percentage of net revenue down for a third straight quarter to 30% - record low since IPO date, down from 36% in Q2 FY23 and down from 78% in Q4 FY22
  • Transition to new broker, LeBeau Excel, expands addressable market for product in Canada and expected to generate 2-3% improvement in customer net margin
  • Partnership secured with RooLife Group to market, sell and distribute Hydralyte products in China –expands Company’s global footprint and unlocks additional potential revenue stream
  • Amazon Canada subscribers grew from zero to 1,383 during the quarter while Amazon US YoY subscription growth is up 4% from 4,026 same time last year to 4,180 subscribers at end of Q3 FY23, despite a heavy reduction in advertising spend
  • Continued execution of stated strategy to reduce expenditure and extend cash reserves through reduced marketing spend following investments in 2022

Financial overview:

Revenue for the quarter increased 7% on PCP (Q3 FY2022: US$2.43m) to US$2.60m, highlighting strong growth and resulting in the second highest quarterly sales result to date.

Quarter on quarter revenue was down slightly, primarily due to the Company’s strategic decision to transition to a new sales broker in Canada. This transition was completed during Q3 FY23 and will result in an expected net customer margin improvement of two to three percentage points.

The transition also led to a slight lag in revenue receipts during Q3 FY23. Q3 FY23’s strong result takes 12-month trailing revenue to US$10.43m.

The Q3 FY2023 revenue result was underpinned by continued strong growth through e- commerce channels, highlighted by Amazon Canada quarterly net sales increasing 60% on the PCP to CAD$0.67m (Q3 FY2022: CAD$0.42m).


Click here for the full ASX Release

This article includes content from The Hydration Pharmaceuticals Company Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

Hydralyte International

Hydralyte International Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Invion Limited

Invion Doses First Patient in Phase I/II Non-Melanoma Skin Cancer Trial

Invion Limited (ASX: IVX) (“Invion” or the “Company”) is pleased to announce the dosing of the first patient in its Phase I/II non- melanoma skin cancer (NMSC) trial conducted at Veracity Clinical Research (Veracity) in Brisbane.

Keep reading...Show less
BPH Global

Seaweed Extraction of Critical Minerals R&D

BPH Global (BP8:AU) has announced Seaweed Extraction of Critical Minerals R&D

Download the PDF here.

Resonance Health Ltd

Resonance Contracted by Major Global Pharma Company for Clinical Drug Trial Worth $13.775 Million over 24 Months

Resonance Health Ltd (ASX: RHT) (Resonance or the Company) advises that it has been contracted by Sun Pharmaceutical Industries Limited, an international, publicly listed pharmaceutical company with global operations (Customer) to be the local Australian sponsor, and to provide clinical research organisation (CRO) services, trial site services, and imaging analysis services (collectively, Services), for their clinical trial in Australia of a new drug compound (Clinical Trial).

Keep reading...Show less
  Island Pharmaceuticals

ISLA-101 Phase 2a/b PROTECT Clinical Trial Progress Update

Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; Island or the Company) is pleased to announce progress on its ISLA-101 Phase 2a/b clinical trial in dengue fever.

Keep reading...Show less
Amplia Therapeutics

Interim Data from Accent Pancreatic Cancer Trial Supports Continuation of Trial

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to report the interim data analysis from the Company’s Phase 2a clinical trial investigating narmafotinib in the treatment of advanced pancreatic cancer (the ACCENT trial). The trial is investigating the combination of the Company’s best-in-class FAK inhibitor narmafotinib with the standard-of-care chemotherapy regimen of gemcitabine and Abraxane®. Data cut-off for the interim analysis is 27 September 2024.

Keep reading...Show less
Hydralyte International

Hydralyte International Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×